CLOPIDOGREL- clopidogrel tablet

Држава: Сједињене Америчке Државе

Језик: Енглески

Извор: NLM (National Library of Medicine)

Активни састојак:

CLOPIDOGREL BISULFATE (UNII: 08I79HTP27) (CLOPIDOGREL - UNII:A74586SNO7)

Доступно од:

NuCare Pharmaceuticals,Inc.

INN (Међународно име):

CLOPIDOGREL BISULFATE

Састав:

CLOPIDOGREL 75 mg

Пут администрације:

ORAL

Тип рецептора:

PRESCRIPTION DRUG

Терапеутске индикације:

•  •  Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke (MI) in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke. Clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Clopidogrel tablets are contraindicated in patients with hyper

Резиме производа:

Clopidogrel Tablets USP, 75 mg are available as pink colored, circular, biconvex, film-coated tablets debossed with L 11 on one side and plain on other side. Tablets are provided as follows: NDC 68071-4031-03 Bottles of 30 Store at 20° to 25°C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].

Статус ауторизације:

Abbreviated New Drug Application

Информативни летак

NuCare Pharmaceuticals,Inc.
----------
.
Revised: 8/2017
Document Id: 55dbd02e-8de2-6b8f-e054-00144ff88e88
34391-3
Set id: 55dbd02e-8de1-6b8f-e054-00144ff88e88
Version: 1
Effective Time: 20170803
NuCare Pharmaceuticals,Inc.

Карактеристике производа

CLOPIDOGREL- CLOPIDOGREL TABLET
NUCARE PHARMACEUTICALS,INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CLOPIDOGREL TABLETS SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CLOPIDOGREL TABLETS.
CLOPIDOGREL TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1997
WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO
LOSS-OF-FUNCTION
ALLELES OF THE CYP2C19 GENE
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING. _
• EFFECTIVENESS OF CLOPIDOGREL DEPENDS ON CONVERSION TO AN ACTIVE
METABOLITE BY THE CYTOCHROME P450
(CYP) SYSTEM, PRINCIPALLY CYP2C19. ( 5.1, 12.3)
• TESTS ARE AVAILABLE TO IDENTIFY PATIENTS WHO ARE CYP2C19 POOR
METABOLIZERS. ( 12.5)
• CONSIDER USE OF ANOTHER PLATELET P2Y12 INHIBITOR IN PATIENTS
IDENTIFIED AS CYP2C19 POOR METABOLIZERS. (
5.1)
RECENT MAJOR CHANGES
Boxed Warning 09/2016
Indications and Usage ( 1.1, 1.2) 09/2016
Dosage and Administration ( 2.1, 2.2) 09/2016
Warnings and Precautions ( 5.1, 5.2, 5.3) 09/2016
INDICATIONS AND USAGE
Clopidogrel is a P2Y
platelet inhibitor indicated for:
• Acute coronary syndrome
-For patients with non-ST-segment elevation ACS [unstable angina
(UA)/non-ST-elevation myocardial infarction
(NSTEMI)], clopidogrel has been shown to reduce the rate of myocardial
infarction (MI) and stroke. ( 1.1)
- For patients with ST-elevation myocardial infarction (STEMI),
clopidogrel has been shown to reduce the rate of MI and
stroke. ( 1.1)
• Recent MI, recent stroke, or established peripheral arterial
disease. Clopidogrel has been shown to reduce the rate of MI
and stroke. ( 1.2)
DOSAGE AND ADMINISTRATION
• Acute coronary syndrome ( 2.1)
- Initiate clopidogrel with a single 300-mg oral loading dose and then
continue at 75 mg once daily
- Initiating clopidogrel without a loading dose will delay
establishment of an antiplatelet effect by several days
• Recent MI, recent stroke, or established peripheral arterial
disease: 75 mg once daily orally without a loading dose ( 2.2)
DOS